Lisa Derosa is a clinician-scientist in immuno-oncology affiliated with Institut Gustave Roussy and Université Paris-Saclay in France. Her research focuses on the role of the gut microbiota in cancer development and response to immunotherapy, with the aim of improving patient stratification and therapeutic outcomes. She has made key contributions to understanding how microbial composition influences resistance and sensitivity to immune checkpoint inhibitors and has co-authored numerous high-impact publications in this field. Lisa is the initiator of Clinicobiome, a translational program integrating microbiome research into clinical oncology, and she oversees multiple clinical cohorts supporting biomarker discovery and therapeutic innovation. She also plays a leading role in large collaborative initiatives, including ONCOBIOME, a European research consortium investigating microbiome-based biomarkers in cancer.